Invitation to Revenio Group Corporation’s Audiocast and Conference Call

Revenio Group Corporation, Press Release, January 29, 2019 at 11.30 EET

Invitation to Revenio Group Corporation’s Audiocast and Conference Call

Revenio Group Corporation's Financial Statement Bulletin 2018 will be published on February 14, 2019 approximately at 9:00 am Helsinki time.

On the same day we will arrange an Audiocast and a Conference Call starting at 11.00 am Helsinki time.

Audiocast

CEO Timo Hildén and CFO Robin Pulkkinen are presenting the results for 2018. The presentations can also be viewed as a real-time webcast (Audiocast) at http://www.revenio.com/investors starting at 11:00 am Helsinki time. A recorded version of the Audiocast presentation will be published by 16:00 pm in the same address.

Conference Call

To ask questions, please join the event conference 5-10 minutes prior to the start time using the Participant Passcode listed below.

Participant Passcode: 11537216#

FI: +358 981 710 310

SE: +46 856 642 651

UK: +44 333 300 08 04

US: +1 631 913 14 22

If you are calling from another location, please use any of the numbers above.

You can also send questions in advance by email to info@revenio.fi by February 14 at 10:00 am. The aim is to answer the questions after the presentation within the time available.

All discussions and presentations are in English.

Revenio Group Corporation

Further information:

CFO Robin Pulkkinen

Tel. +358 50 505 9932

robin.pulkkinen@revenio.fi

www.revenio.fi

www.ventica.fi

DISTRIBUTION:

Major media

www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2017, Revenio Group's net sales totaled EUR 26.8 million, with its operating margin, excluding non-recurring items, standing at 35.5%. Revenio Group Corporation is listed on Nasdaq Helsinki.